SABCS 2018 — Adding adjuvant capecitabine fails to extend survival in early TNBC


  • Relazioni sui congressi in Oncologia
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Adding adjuvant capecitabine to standard treatment for early triple-negative breast cancer (TNBC) failed to significantly extend disease-free survival (DFS) or OS in the phase 3 CIBOMA_GEICAM trial.

Why this matters

  • Some benefit was observed in a subset of patients with nonbasal-like disease, but the findings should be interpreted with caution.

Study design

  • Trial of 876 patients with TNBC who received (neo)adjuvant therapy with standard anthracycline and/or taxane-containing chemotherapy and who underwent surgery with negative margins.
  • Patients were randomly assigned to 8 cycles of capecitabine or observation.
  • Funding: Roche.
  • Funding: Dr. Martín has received speaker honoraria from Pfizer and Lilly; research grants from Novartis and Roche; and advisory board honoraria from AstraZeneca, Novartis, Roche-Genentech, Pfizer, GlaxoSmithKline, PharmaMar, Taiho Oncology, and Lilly. 

Key results

  • Median follow-up, 7.34 years.
  • 5-year DFS was similar with capecitabine vs observation (79.6% vs 76.8%; HR, 0.82; P=.1353).
    • HR remained nonsignificant (aHR, 0.79; P=.082) after adjustment for location, prior (neo)adjuvant therapy, number of nodes involved, and TNBC phenotype.
  • 5-year OS was similar with capecitabine vs observation (86.2% vs 85.9%; HR, 0.92; P=.6228).
  • In a subset of patients with nonbasal-like phenotype (28.3%):
    • 5-year DFS was higher with capecitabine (82.6% vs 72.9%; HR, 0.53; P=.02).
    • OS was also higher with capecitabine (89.5% vs 79.6%; HR, 0.42; P=.007).

Limitations

  • Fewer than expected relapses in the observation group.